Apoptosis and cancer chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Disseminated cancers often exhibit resistance to systemic therapies, posing a significant clinical challenge.
• Traditional drug discovery has focused on antiproliferative agents targeting DNA, but this has limited success against resistant tumors.
• Tumor cell resistance may arise from enhanced survival mechanisms, specifically a reduced tendency to undergo programmed cell death (apoptosis).

Purpose of the Study:

• To investigate the molecular basis of differential survival potential in intestinal stem cells.
• To elucidate the role of specific genes, such as bcl-2 and p53, in cancer cell survival and drug resistance.
• To identify novel therapeutic strategies targeting cell survival pathways for overcoming drug resistance in disseminated cancers.

Main Methods:

• Comparative analysis of stem cell survival mechanisms in the colon and small intestine.
• Molecular investigation of gene expression patterns, including bcl-2 and p53.
• Assessment of drug resistance mechanisms in tumor cells related to apoptosis regulation.

Main Results:

• Colonic stem cells exhibit enhanced survival due to bcl-2 expression and a blunted p53 response to DNA damage.
• This survival advantage allows damaged cells to persist, contributing to cancer development and progression.
• Sustained bcl-2 expression in tumor cells confers resistance to drug-induced DNA damage via non-classical pathways.

Conclusions:

• The inherent resistance of disseminated cancers is linked to tumor cells' enhanced survival potential and evasion of apoptosis.
• Targeting and attenuating cancer cell survival mechanisms represents a promising strategy for improving drug treatment efficacy.
• Understanding the molecular underpinnings of bcl-2 and p53 in cancer cell survival is crucial for developing next-generation cancer therapies.